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The current concept of Good Manufacturing Practices (GMP)
emphasizes that the quality of pharmaceutical products must be
constructed during the overall process cycle. Quality control
department plays an important role in quality-by-design (QbD)
concept, since it demands the acquisition of reliable in-process
analytical data [1,2]. Many important decisions are based on thesity. Production and hosting by Elsev
1
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Lourenço).
an Jiaotong University.analytical data of quality control department and it is important to
have indication of the quality of these results [3,4].
As a consequence of these requirements, quality control
department should demonstrate the quality of their results and
their ﬁtness for purpose by giving a measure of the conﬁdence that
can be placed on the results. One useful measure of this is
measurement uncertainty. Measurement uncertainty provides addi-
tional information that may be useful for compliance or non-
compliance decisions [4–7].
The evaluation of uncertainty requires a detailed study of all
possible sources of uncertainty. However, it is essential that the
effort expanded should not be disproportionate. A preliminary
study may identify the most signiﬁcant sources of uncertainty and
the value obtained for the combined uncertainty may be almost
entirely controlled by the major contributions [4,8].
The uncertainty on the results may arise from many possible
sources, including sampling, matrix effects and interferences,
environmental conditions, uncertainties of mass and volumetricier B.V. All rights reserved.
M.A.L. Traple et al.2equipment, uncertainties of spectrophotometric and chromato-
graphic equipment, uncertainties of biological and microbiological
responses, purity of reagents and chemical reference substances,
method validation and random variability [9–22].
Typically, these sources of uncertainties are divided into two
types: Type A – random error and Type B – systematic error.
Random error arises from unpredictable variations. These random
effects give rise to variations in repeated observations. The random
error can usually be reduced by increasing the number of
observations. Systematic error is a component of errors which
remain constant or vary in a predictable way. It is independent of
the number of observations. The result should be corrected for all
recognized signiﬁcant systematic errors [4,8,23].
The steps involved in uncertainty estimation are: (1) speciﬁca-
tion of measurand, (2) identiﬁcation of uncertainty sources, (3)
quantiﬁcation of uncertainty components, and (4) calculation of
combined and expanded uncertainty [4,24,25]. A summary of
these steps is presented in Table 1.
In pharmaceutical analysis, the sources of uncertainty may arise
from sampling, environment conditions, method validation, instru-
ments, weighting and dilutions, reference materials, chemical,
microbiological and others aspects. A list of the main sources of
uncertainty is presented in Fig. 1.
A complete report of a measurement result should include a
description of the methods used to calculate the result and its
uncertainty. Usually, the result is stated together with the expanded
uncertainty. The uncertainty may be a useful tool to assess
compliance or the limits may be set with some allowance for
measurement uncertainties [4,7].
The aim of this work was to evaluate and discuss the estimation
of measurement uncertainty in pharmaceutical analysis and its
application
2. Uncertainty in pharmaceutical analysis
Currently, several tests and assays are performed by quality control
department of pharmaceutical industries, such as content and/or
biological potency of active pharmaceutical ingredient (API), limit
of organic and/or inorganic impurities, pH, microbiological and
endotoxin limits. In this context, the pharmacists need to have a
good understanding of several techniques, such as chemical, spectro-
photometric, chromatographic and microbiological methods [26,27].
2.1. Uncertainty in spectrophotometric and chromatographic
analysis
Soovälli and collaborators [17] investigated the most important
uncertainty sources that affect analytical UV–vis spectrophoto-
metric measurements. According to their results, physical sourcesTable 1 Steps involved in uncertainty estimation.
Step What to do? How to do?
Speciﬁcation of measurand Deﬁne what is being measured, including a
Identiﬁcation of uncertainty sources List the possible sources of uncertainty. A c
uncertainty sources and how they relate to e
Quantiﬁcation of uncertainty
components
Measure or estimate the uncertainty compon
uncertainties may be obtained from method
chemical reference substances and experimen
Calculation of combined and
expanded uncertainties
Express all uncertainties components as stan
uncertainty. Multiply the combined standard
order to obtain an expanded uncertainty [4].of uncertainty often have signiﬁcantly lower contributions than
chemical sources. The calibration equations also have a signiﬁcant
contribution to the uncertainty in UV–vis spectrophotometric
analysis [19].
Saviano and Lourenço [28] studied the uncertainties sources
associated with linezolid determination by UV spectrophotometry.
According to their results, the contributions of precision, linearity
and weight of linezolid reference standard are the most signiﬁcant,
contributing with about 77% of the overall uncertainty. The
Eurachem procedure was also compared to Monte Carlo simula-
tion results. The ﬁnal result and its uncertainty estimated by the
Eurachem procedure was found to be about 93.9272.12% and the
95% conﬁdence interval obtained from Monte Carlo simulation
was 93.9272.06%. Therefore, the Eurachem procedure can be
considered reasonable for the estimation of measurement uncer-
tainty of linezolid by UV spectrophotometry.
Paakkunainen and collaborators [29] studied the measurement
uncertainty of lactase-containing tablets analyzed with FTIR. They
reported that homogeneity of tablets was the most relevant source
of uncertainty, and nearly 20 tablets had to be analyzed for a 5%
uncertainty level.
Anglov and collaborators [13] performed similar studies con-
cerning reverse phase high performance liquid chromatography
(RP-HPLC). In this study, they evaluated the uncertainty con-
tributions of repeatability of peak area, dilutions factors, reference
materials and sampling. Sampling, calibration and repeatability
were the most signiﬁcant sources which affect combined uncer-
tainty. As it occurs in UV–vis spectrophotometric analysis,
calibration equations also have a signiﬁcant contribution to the
uncertainty in liquid chromatography [20].
Leito and collaborators [30] studied the inﬂuence of peak
integration, nonlinearity of calibration curve and other sources of
uncertainty in chromatographic assay of simvastatin in drug
formulation. According to their results, uncertainty estimated for
single-point calibration is only slightly larger than a ﬁve-point
calibration model.
Results obtained by our research group (not yet published)
indicate that accuracy, linearity and precision contribute with
about 70% of overall uncertainty in determination of linezolid by
RP-HPLC. According to Monte Carlo simulation results, the
procedure for estimation of the measurement uncertainty can be
considered appropriate. The ﬁnal result and its 95% conﬁdence
interval estimated by the Eurachem procedure was found to
be 95.1372.51%, while Monte Carlo simulation yielded 95.147
2.46%.
Lecomte and collaborators [31] established the measurement
uncertainty for the determination of cidofovir in human plasma by
hydrophilic interaction chromatography. They compared two
approaches for estimation of measurement uncertainty: fromrelationship between the result and the input quantities upon it depends [4].
ause-and-effect diagram (Fig. 1) is a very convenient way of listing the
ach other [4,25].
ent associated with each potential source of uncertainty identiﬁed. These
validation data, calibration certiﬁcate of instruments, purity of reagents and
tal studies [4,24].
dard deviations. Two simple rules may be used to calculate the combined
uncertainty by a chosen coverage factor (at the required level of conﬁdence) in
uncertainty
Measurement
aspects
Chemical
Others
materials
Reference
aspects
Microbiological
dilutions
Weight and
Validation
Instrument
Sampling
Environment
Gas/Air atmosphere
Pressure
Light intensity
Humidity
Temperature
Lot size
Sample size
Sample stability
Sample preparation
Homogeneity
aspects
Specific
response
Range of
Sensitivity
Repeatability
aspects
Physical
LOD / LOQ
Specificity
Selectivity /
Linearity
Precision
Accuracy
apparatus
Other
Micropippets
pipettes
Volumetric
flasks
Volumetric
Balance
of microorganism
Type and amount
activity of sample
Antimicrobial
Sterility of media
of media
Growth promotion
conditions
Incubation
potency
Biological
impurities
Inorganic
impurities
Organic
water
Amount of
purity
Chemical
knowledge
Operator
Statistical aspects
design
Experimental
Matrix interference
conditions
Chromatographic
interference
Matrix
reaction
Time of
pH of solutions
of solutions
Concentration
Stoichiometry
Fig. 1 Main sources of uncertainties affecting measurement uncertainty in pharmaceutical analysis [4,25].
Uncertainty in pharmaceutical analysis 3method validation and from routine application. They found that
estimations obtained during method validation underestimated
those obtained from routine applications and that this magnitude
of underestimation was related to cidofovir concentration.
2.2. Uncertainty in microbiological analysis
The most signiﬁcant sources of uncertainty in microbiological
assay were studied by Lourenço and collaborators [18] and
Lourenço [20]. The uncertainty was estimated based on the
method validation data [18], which included precision and
accuracy. The uncertainty may be estimated based on the
variability of inhibition zone diameter within and between dishes
[20]. In another study, Lourenço [32] evaluated the uncertainties
associated with reference and standard weighing and dilutions,
such as balance, volumetric ﬂasks and pipettes; and uncertainty
estimated based on the variability of inhibition zone diameters of a
validated microbiological assay for apramycin in soluble powder
[33]. According to the results, the variability of inhibition zone
diameters (within and between plates) was the most signiﬁcant
source of uncertainty.
In microbiological limits the result is obtained by counting the
colony forming units (CFU). Traditionally, microbiological uncer-
tainty estimates have been based on replicate measurements and on
the Poisson theory. However, other aspects such as antimicrobial
activity of product, growth promotion of culture media and
speciﬁc characteristics of microorganisms should be considered
as potential sources of uncertainty [9,15,34].
Lourenço and collaborators [16] established a procedure to
estimate uncertainty of LAL gel-clot test. The usual form ofestimating and informing the uncertainty in qualitative analysis
(‘pass/fail’) is the use of false-negative and false-positive
responses [35,36]. Temperature, time of incubation, pH, sensitivity
of LAL and interference of product were evaluated as sources of
uncertainty [16,21].
2.3. Uncertainty in chemical and physical analysis
The estimation of uncertainty in routine pH measurement was
evaluated by Leito and collaborators [12]. The study included
physical and chemical sources of uncertainty. According to the
results, the uncertainty was the lowest near pH 7 and increased
when moving to pH 2 or 11 [12]. Chui and collaborators [11]
studied the precision of Karl Fischer for water determination. They
identiﬁed kinetic and stoichiometric factors, matrix interference
and mass of sample as potential sources of uncertainty [11].
Paakkunainen and collaborators [37] studied the uncertainties
associated with dissolution test of drug release. According to their
results, uncertainties associated with sampling error, total analy-
tical error and the error arising from the heterogeneous samples
were the main sources of uncertainty. Further studies should be
performed in order to study the uncertainty sources associated with
disintegration, friability, hardness and other tests and assays
employed in pharmaceutical analysis.3. Applications of uncertainty in pharmaceutical analysis
Decisions of compliance or non-compliance in pharmaceutical
industry are based on analytical results obtained by quality control
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Fig. 2 Evaluation of compliance or non-compliance based on
analytical result and its uncertainty (speciﬁcation limits from 95% to
105%) [4,7].
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results and should be considered when testing a sample against
legal speciﬁcations. It can be a critical situation when the result is
so close to the limits that its uncertainty affects decision [4,7].
Typically, we have four situations that must be considered:
result and its uncertainty within speciﬁcation interval (Fig. 2A);
result within the speciﬁcation interval, but its uncertainty out of
speciﬁcation (Fig. 2B); result out of speciﬁcation, but its uncer-
tainty within the speciﬁcation interval (Fig. 2C); and result and its
uncertainty out of speciﬁcation (Fig. 2D) [4,7].
This approach is very useful in the assessment of compliance or
non-compliance of in-process and ﬁnal pharmaceutical products.
Uncertainty cannot replace method validation, but it is a way to
provide complete information about a sample. If the uncertainty is
unknown, the information is not complete; therefore this decision
might be impossible. Uncertainty may be useful in the develop-
ment, validation and comparison of analytical methods [3,4,22,38].
3.1. Uncertainty in pharmaceutical equivalence assessment
Pharmaceutical equivalence is an important step to conﬁrm
similarity and interchangeability in pharmaceutical products,
particularly regarding those that will not be tested for bioequiva-
lence/relative bioavailability. Lourenço and collaborators [39]
compared t-student difference test and two one-side equivalence
tests in the assessment of pharmaceutical equivalence. Uncertainty
may be an alternative to assess pharmaceutical equivalence, once it
provides information to compare reference and test (similar or
generic) products.
Okamoto and collaborators [40] established a procedure to
estimate the measurement uncertainty for metronidazole quantiﬁ-
cation by RP-HPLC and applied it in the assessment of pharma-
ceutical equivalence. The measurement uncertainty approach was
compared to the two one-sided tests (TOST) for equivalence [40].
According to their results, both TOST and uncertainty approaches
allow us to assess pharmaceutical equivalence among test (generic
or similar) and brand-name drugs [40].
3.2. Uncertainty in stability studies
Uncertainty can also be useful for investigating out of speciﬁcation
results in stability study of pharmaceutical products [41]. Use of
warning and action lines—time values around the established shelf
life that takes into account the measurement uncertainty—may behelpful when the measured property is increasing or decreasing
with time [38]. This approach may provide additional information
regarding shelf life of product and estimation of the producer's and
customers' risk of the established shelf life [41].
In another study, Magari [42] evaluated how the number of lots
and replicates analyzed in stability study affect the estimation of
shelf life and its measurement uncertainty. According to his
conclusions, the number of lots and replicates would be deﬁned
based on measurement uncertainty, experimental design and other
practical considerations.4. Conclusions
We conclude that uncertainty provides complete information about
an analytical result and it plays an important role in decision of
compliance or non-compliance of in-process and ﬁnal pharmaceu-
tical products as well as in the assessment of pharmaceutical
equivalence and stability study of drug products.
Acknowledgments
This work was supported by Fundação de Apoio à Pesquisa do
Estado de São Paulo (FAPESP).
References
[1] International Conference on Harmonisation (ICH), Q8 Pharmaceutical
Development, Food and Drug Administration, Rockville, 2006.
[2] T.J.A. Pinto, T.M. Kaneko, A.F. Pinto, Controle biológico de
qualidade de produtos farmacêuticos, correlatos e cosméticos, 3rd
ed., Atheneu, São Paulo, 2010, p 780.
[3] S. Küppers, The application of the measurement uncertainty concept
to in-process control in pharmaceutical development, Accredit. Qual.
Assur. 2 (1997) 30–35.
[4] Eurachem/Citac Guide, Quantifying Uncertainty in Analytical Mea-
surement, 3rd ed., Eurachem/CITAC Working Group, UK, 2012.
[5] N. Mueller, Introducing the concept of uncertainty of measurement in
testing in association with the application of the standard ISO/IEC
17025, Accredit. Qual. Assur. 7 (2002) 79–80.
[6] ISO/IEC 17025,2005 General Requirements for the Competence of
Testing and Calibration Laboratories, International Organization for
Standardization, Switzerland, 2005.
[7] E. Desimoni, B. Brunetti, Uncertainty of measurement and confor-
mity assessment: a review, Anal. Bioanal. Chem. 400 (2011)
1729–1741.
[8] ISO GUM, Guide to the Expression of Uncertainty in Measurement,
Joint Committee for Guides in Metrology (Working Group 1), France,
2008.
[9] R.M. Niemi, S.I. Niemelã, Measurement uncertainty in microbiolo-
gical cultivation methods, Accredit. Qual. Assur. 6 (2001) 372–375.
[10] L. Brüggemann, R. Wennrich, Evaluation of measurement uncertainty
for analytical procedures using a linear calibration function, Accredit.
Qual. Assur. 7 (2002) 269–273.
[11] Q.S.H. Chui, H.N Antonoff, J.C Olivieri, Utilização de índices r e R
obtidos de programas interlaboratoriais para o controle de precisão de
método analítico: determinação de água por Karl Fischer, Quim. Nova
25 (2002) 657–659.
[12] I. Leito, L. Strauss, E. Koort, et al., Estimation of uncertainty in
routine pH measurement, Accredit. Qual. Assur. 7 (2002) 242–249.
[13] T. Anglov, K. Byrialsen, J.K. Carstensen, et al., Uncertainty budget
for ﬁnal assay of a pharmaceutical product based on RP-HPLC,
Accredit. Qual. Assur. 8 (2003) 225–230.
[14] S. Wunderli, Uncertainty and sampling, Accredit. Qual. Assur. 8
(2003) 90.
Uncertainty in pharmaceutical analysis 5[15] F.R. Lourenço, C.M.O. Amaral, J.C. Azevedo, et al., Estimativa da
incerteza de medição em contagem microbiana pelo método de
semeadura em profundidade a partir dos resultados de validação,
Braz. J. Pharm. Sci. 40 (2004) 181–183.
[16] F.R. Lourenço, T.M. Kaneko, T.J.A. Pinto, Estimativa da incerteza
em ensaio de detecção de endotoxina bacteriana pelo método de
geliﬁcação, Braz. J. Pharm. Sci. 41 (2005) 437–443.
[17] L. Sooväli, E.I. Rõõm, A. Kütt, et al., Uncertainty sources in UV–vis
spectrophotometric measurement, Accredit. Qual. Assur. 11 (2006)
246–255.
[18] F.R. Lourenço, T.M. Kaneko, T.J.A. Pinto, Evaluating measurement
uncertainty in microbiological assay of vancomycin from methodology
validation data, J. AOAC Int. 90 (2007) 1383–1386.
[19] K.H. Hsu, C. Chen, The effect of calibration equations on the
uncertainty of UV–vis spectrophotometric measurements, Measure-
ment 43 (2010) 1525–1531.
[20] F.R. Lourenço, Simple estimation of uncertainty in the quantiﬁcation
of cefazolin by HPLC and bioassay, J. Chromatogr. Sep. Tech. 3
(2012) 1–3.
[21] F.R. Lourenço, T.S. Botelho, T.J.A. Pinto, How pH, temperature, and
time of incubation affect false-positive responses and uncertainty of
the LAL gel-clot test, PDA J. Pharm. Sci. Technol. 66 (2012) 542–546.
[22] M.L.J. Weitzel, The estimation and use of measurement uncertainty
for a drug substance test procedure validated according to USP
〈1225〉, Accredit. Qual. Assur. 17 (2012) 139–146.
[23] VIM International Vocabulary of Basic and General Terms in
Metrology, 2nd ed, Joint Committee for Guides in Metrology
(Working Group 2), France, 2006.
[24] A. Williams, Introduction to measurement uncertainty in chemical
analysis, Accredit. Qual. Assur. 3 (1998) 92–94.
[25] S.L.R. Ellison, V.J. Barwick, Estimating measurement uncertainty:
reconciliation using a cause and effect approach, Accredit. Qual.
Assur. 3 (1998) 101–105.
[26] Farmacopéia Brasileria (FB), 5th ed, Agência Nacional de Vigilância
Sanitária, Brasília, 2010.
[27] United States Pharmacopeia (USP), 35th ed., United States Pharma-
copeial Convention, Rockville, 2012.
[28] A.M. Saviano, F.R. Lourenço, Uncertainty evaluation for determining
linezolid in injectable solution by UV spectrophotometry, Measure-
ment 46 (2013) 3924–3928.
[29] M. Paakkunainen, J. Kohonen, S.P. Reinikainen, Measurement
uncertainty of lactase-containing tablets analyzed with FTIR,J. Pharm. Biomed. Anal. (2013) http://dx.doi.org/10.1016/j.jpba.
2013.10.004.
[30] S. Leito, K. Mölder, A. Künnapas, et al., Uncertainty in liquid
chromatographic analysis of pharmaceutical product: inﬂuence of
various uncertainty sources, J. Chromatogr. A 1121 (2006) 55–63.
[31] F. Lecomte, C. Hubert, S. Demarche, et al., Comparison of the
quantitative performances and measurement uncertainty estimates
obtained during method validation versus routine applications of a
novel hydrophilic interaction chromatography method for the deter-
mination of cidofovir in human plasma, J, Pharm. Biomed. Anal. 57
(2012) 153–165.
[32] F.R. Lourenço, Uncertainty measurement of microbiological assay for
apramycin soluble powder, Lat. Am. J. Pharm. 32 (2013) 640–645.
[33] F.R. Lourenço, E.A. Barbosa, T.J.A. Pinto, Microbiological assay for
apramycin soluble powder, Lat. Am. J. Pharm. 30 (2011) 554–557.
[34] European Co-Operation for Accreditation, EA-4/10, Accreditation for
Microbiological Laboratories, EA, France: working group food of the
EA Laboratory Committee in collaboration with Eurachem, 2002.
[35] S.L.R. Ellison, Uncertainties in qualitative testing and analysis,
Accredit. Qual. Assur. 5 (2000) 346–348.
[36] S.L.R. Ellison, S. Gregory, W.A. Hardcastle, Quantifying uncertainty
in qualitative analysis, Analyst 123 (1998) 1155–1161.
[37] M. Paakkunainen, S. Matero, J. Ketolainen, et al., Uncertainty in
dissolution test of drug release, Chemom. Intell. Lab. Syst. 97 (2009)
82–90.
[38] S. Küppers, A validation concept for purity determination and assay
in the pharmaceutical industry using measurement uncertainty and
statistical process control, Accredit. Qual. Assur. 2 (1997) 338–341.
[39] F.R. Lourenço, T.J.A. Pinto, Assessment of pharmaceutical equiva-
lence: difference test or equivalence test? Lat. Am. J. Pharm. 31
(2012) 591–604.
[40] R.T. Okamoto, M.A.L. Traple, F.R. Lourenço, Uncertainty in the
quantiﬁcation of metronidazole in injectable solution and its applica-
tion in the assessment of pharmaceutical equivalence, Curr. Pharm.
Anal. 9 (2013) 355–362.
[41] I. Kuselman, I. Schumacher, F. Pennecchi, et al., Long-term stability
study of drug products and out-of-speciﬁcation test results, Accredit.
Qual. Assur. 16 (2011) 615–622.
[42] R.T. Magari, Uncertainty of measurement and error in stability
studies, J, Pharm. Biomed. Anal. 45 (2007) 171–175.
